R&D Trends

SBRI Healthcare launches new competition, $4.2M available to small businesses

Wednesday, May 21, 2014 01:27 PM

SBRI Healthcare, an NHS England funded initiative to develop innovative products and services that address unmet health needs, has launched the latest SBRI Healthcare competition with $4.2 million available to support small business.

More... »

WIRB Copernicus Group

Neurotrope, Stanford expand collaboration

Wednesday, May 21, 2014 01:25 PM

Neurotrope has signed an agreement with Stanford University to study and investigate certain analogs of bryostatin, referred to as "bryologs," as potential clinical candidates for the treatment of various neurological disorders.

More... »

CRF Health eCOA webinar series

Inovio Pharmaceuticals acquires DNA therapies from University of Pennsylvania

Wednesday, May 21, 2014 01:21 PM

Inovio Pharmaceuticals has acquired worldwide rights (excluding China) for early preclinical therapies addressing Alzheimer's disease and multiple sclerosis based on the academic research of Dr. Bin Wang, a professor at Fudan University's Shanghai Medical College, who worked closely with Dr. David Weiner at the University of Pennsylvania. Inovio will make clinical and regulatory milestone payments to the University.

More... »

Kymab receives $40M investment from Wellcome Trust, Gates Foundation

Monday, May 19, 2014 01:25 PM

The Bill & Melinda Gates Foundation and the Wellcome Trust each invested $20 million in Kymab, a monoclonal antibody biopharmaceutical company, to enable Kymab to maximize its Kymouse platform and advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies in areas of significant unmet medical need, including cancer and inflammation.

More... »

AstraZeneca, MRC Laboratory of Molecular Biology to launch joint research fund

Friday, May 16, 2014 12:47 PM

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology (MRC LMB) to fund a range of preclinical research projects aimed at better understanding the biology of disease.

More... »

Despite fewer healthcare deals, corporate venture capital booming

Friday, May 16, 2014 12:39 PM

By Ronald Rosenberg
CenterWatch Staff Writer

While last year’s boom in corporate venture capital financing continues to expand in some business sectors, the healthcare space raised only $288 million in 23 deals in the first quarter of 2014—the lowest in five quarters.

More... »

AC Immune, Piramal Imaging ink agreement for Alzheimer's disease

Thursday, May 15, 2014 01:27 PM

AC Immune, a Swiss-based biopharmaceutical company, and Piramal Imaging, a division of Piramal Enterprises, have entered into an exclusive worldwide license agreement for the research, development and commercialization of AC Immune's Tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of Alzheimer's disease and potential Tau-related disorders.

More... »

Bristol-Myers Squibb, Celldex Therapeutics to collaborate

Thursday, May 15, 2014 01:24 PM

Bristol-Myers Squibb and Celldex Therapeutics have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a phase I/II study.

More... »

Ligand, Omthera ink agreement for dyslipidemia

Thursday, May 15, 2014 01:21 PM

Ligand Pharmaceuticals has entered into a licensing agreement and research collaboration with Omthera Pharmaceuticals, a wholly-owned subsidiary of AstraZeneca, for the development of products to treat dyslipidemia, including hypertriglyceridemia.

More... »

Incyte, MedImmune collaborate on immuno-oncology clinical trial

Wednesday, May 14, 2014 01:30 PM

Incyte, a Wilmington, Del.-based biopharmaceutical company, and MedImmune, the global biologics R&D arm of AstraZeneca, have entered into a clinical study collaboration. The phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs